DeSoto Peptides Research Journal | October 2026
Body weight is only one measurement of metabolic health. Two individuals can weigh exactly the same while having very different fat distributions, skeletal muscle composition, and metabolic risk profiles.
This distinction has become increasingly important in modern peptide research, particularly when examining compounds that influence different biological pathways.
Retatrutide and Tesamorelin represent two distinct approaches to investigating body composition.
Retatrutide has demonstrated substantial reductions in overall body weight through its activity at three metabolic hormone receptors. Tesamorelin, meanwhile, has been clinically investigated for its relationship with visceral abdominal fat, growth hormone secretion, and fat distribution.
Their different mechanisms raise an important scientific question:
How do overall weight regulation and targeted changes in visceral fat differ, and what can each research pathway teach us about metabolic health?
Understanding that distinction provides valuable context for evaluating the individual research surrounding these compounds.
Why Body Composition Matters More Than Weight Alone
Traditional weight-management research has often emphasized total body weight, body mass index (BMI), and waist circumference.
Although these measurements provide useful information, they cannot fully describe the body's internal composition.
Body composition includes several important components:
Total fat mass
Lean body mass
Skeletal muscle
Visceral adipose tissue
Subcutaneous adipose tissue
Regional fat distribution
Changes in these measurements do not always occur proportionally.
An individual can experience a substantial reduction in body weight without losing the same percentage of visceral fat, subcutaneous fat, and lean tissue.
Likewise, certain metabolic changes can occur without a dramatic change in total body weight.
This is particularly relevant when comparing Retatrutide and Tesamorelin research because their clinical studies have examined different primary outcomes.
What Is the Difference Between Visceral Fat and Subcutaneous Fat?
Not all stored body fat is located in the same place or serves identical biological functions.
Two major types of adipose tissue are particularly relevant to metabolic research.
Visceral Adipose Tissue (VAT)
Visceral fat is located deep within the abdominal cavity, surrounding internal organs.
Excess visceral adipose tissue has been associated with several metabolic and cardiovascular risk factors, including:
Insulin resistance
Abnormal cholesterol and triglyceride levels
Altered inflammatory signaling
Increased cardiometabolic risk
Metabolic dysfunction
Visceral adipose tissue is metabolically active and contributes to signaling processes involved in glucose and lipid regulation.
Researchers are interested in visceral fat because its distribution may provide information beyond total body weight alone.
Subcutaneous Adipose Tissue (SAT)
Subcutaneous fat is stored directly beneath the skin.
It contributes to energy storage, thermal insulation, and other physiological functions.
Although excess fat accumulation may contribute to metabolic concerns, subcutaneous and visceral fat have different biological relationships with metabolic health.
A reduction in visible abdominal fat does not necessarily reveal how much visceral adipose tissue has changed.
How Researchers Measure Visceral Fat
Researchers commonly use imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) to evaluate fat compartments.
These methods allow investigators to examine changes in visceral and subcutaneous adipose tissue separately.
This distinction becomes especially important when evaluating compounds whose studies focus on fat distribution rather than total body weight.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), sometimes referred to as growth hormone-releasing factor.
Its primary mechanism involves stimulating growth hormone secretion through receptors in the pituitary gland.
Unlike compounds that directly activate metabolic receptors involved in appetite and satiety, Tesamorelin acts through the body's growth hormone regulatory system.
This pathway has important relationships with lipid metabolism, protein metabolism, IGF-1 signaling, and body composition.
Understanding the Growth Hormone Pathway
The growth hormone system involves several stages of biological signaling.
Step 1: GHRH receptor activation
Growth hormone-releasing hormone receptors in the pituitary gland receive signals that influence growth hormone secretion.
Step 2: Growth hormone release
Activation of these receptors stimulates the pituitary gland to release growth hormone into circulation.
Step 3: IGF-1 signaling
Growth hormone promotes production of insulin-like growth factor-1, or IGF-1, particularly through hepatic activity.
Step 4: Metabolic responses
Growth hormone and IGF-1 participate in processes involving tissue growth, protein metabolism, lipid utilization, and other physiological functions.
These relationships help explain why Tesamorelin has attracted interest in research involving abnormal fat distribution.
However, increased growth hormone or IGF-1 levels do not automatically establish improved physical performance, muscle preservation, or long-term metabolic health.
What Clinical Studies Show About Tesamorelin and Visceral Fat
One of the most significant Tesamorelin clinical trials was published in The New England Journal of Medicine in 2007.
The study evaluated 412 adults with HIV-associated abdominal fat accumulation.
Researchers used CT imaging to evaluate changes in visceral adipose tissue over 26 weeks.
Clinical Trial Findings
MeasurementTesamorelinPlaceboVisceral adipose tissue change−15.2%+5.0%Study duration26 weeks26 weeks
The study also examined triglycerides, cholesterol measurements, and IGF-1 levels.
Participants receiving Tesamorelin experienced improvements in several lipid measurements alongside reductions in visceral adipose tissue.
IGF-1 levels also increased, consistent with the compound's activity through the growth hormone pathway.
These findings provided important clinical evidence that Tesamorelin could influence visceral fat accumulation in the specific population studied.
An important distinction: These results came from adults with HIV-associated abdominal fat accumulation. They do not establish identical outcomes in otherwise healthy individuals or people seeking general weight loss.
View the Published Tesamorelin Clinical Trial
Tesamorelin and Liver Fat Research
Visceral fat is not the only area where Tesamorelin has been investigated.
Researchers have also examined its relationship with fat accumulation within the liver.
The liver plays a central role in glucose regulation, lipid metabolism, and energy processing.
Excess liver fat can be associated with metabolic dysfunction and may contribute to progressive liver disease.
The 2019 Tesamorelin Liver Fat Study
A randomized, double-blind clinical trial published in The Lancet HIV investigated Tesamorelin in 61 adults living with HIV who also had nonalcoholic fatty liver disease.
Researchers used magnetic resonance spectroscopy to measure hepatic fat fraction.
Participants were followed for 12 months.
The study reported that Tesamorelin reduced liver fat compared with placebo, with an approximately 37% relative reduction in the Tesamorelin group from baseline.
Researchers also examined changes in liver tissue and metabolic measurements.
These results expanded interest in the relationship between growth hormone signaling, abdominal fat distribution, and hepatic metabolism.
However, the findings were obtained in a specific clinical population and do not establish Tesamorelin as a general treatment for fatty liver disease.
View the Published Liver Fat Study
Where Does Retatrutide Fit Into Body Composition Research?
Retatrutide approaches metabolic regulation through a different pathway.
It is an investigational triple receptor agonist that activates GLP-1, GIP, and glucagon receptors.
These receptors influence appetite, glucose regulation, and energy balance.
In May 2026, Eli Lilly reported that participants receiving 12 mg Retatrutide in its TRIUMPH-1 Phase 3 study experienced an average body-weight reduction of 28.3% after 80 weeks under the reported efficacy analysis.
The same research program has examined changes in waist circumference and several metabolic risk markers.
These findings establish substantial effects on total body weight, but total weight reduction and visceral fat reduction are not interchangeable measurements.
The relevant distinction is that Retatrutide research emphasizes broad changes in body weight and metabolic regulation, whereas Tesamorelin's established clinical evidence focuses on specific fat distribution abnormalities.
View Retatrutide Phase 3 Results
For a more detailed explanation of Retatrutide's triple receptor mechanism, see our dedicated Retatrutide research overview.
Why Are Retatrutide and Tesamorelin Discussed Together?
Scientific interest in Retatrutide and Tesamorelin centers on the relationship between whole-body energy regulation and regional fat metabolism.
Their mechanisms are fundamentally different.
Retatrutide: Overall Energy Balance
Retatrutide influences hormonal pathways involved in food intake, glucose regulation, and energy metabolism.
Its major clinical findings involve total body-weight reduction and improvements in measured metabolic risk factors.
Tesamorelin: Growth Hormone and Fat Distribution
Tesamorelin stimulates growth hormone signaling through the GHRH receptor.
Its clinical evidence demonstrates measurable changes in visceral adipose tissue among adults with HIV-associated lipodystrophy.
The Scientific Connection
Overall weight reduction and redistribution or reduction of specific fat compartments are related but distinct biological outcomes.
Retatrutide and Tesamorelin provide examples of how different signaling pathways can influence these separate aspects of body composition.
This makes their respective research interesting to compare.
However, different mechanisms do not establish that the compounds work better together.
Controlled human studies have not demonstrated that combining Retatrutide with Tesamorelin produces greater visceral fat loss, improved muscle preservation, or superior metabolic outcomes.
Could Growth Hormone Signaling Influence Body Composition During Weight Loss?
Substantial weight reduction can involve changes in multiple tissue compartments.
Depending on the individual and circumstances, these changes may include body fat, water, glycogen, and lean tissue.
Because growth hormone influences protein and lipid metabolism, scientists have investigated its relationship with body composition.
Growth hormone participates in processes associated with lipolysis, the breakdown of stored triglycerides into fatty acids and glycerol.
IGF-1 also participates in tissue growth and metabolic signaling.
However, these biological functions do not establish that increasing growth hormone signaling automatically preserves skeletal muscle during weight reduction.
Muscle Mass Versus Lean Mass
A critical distinction in body-composition research is the difference between lean body mass and skeletal muscle mass.
Lean mass includes more than muscle tissue. It also includes water, organs, and other nonfat components.
Consequently, increases in measured lean mass do not necessarily indicate improvements in muscle strength or functional performance.
This distinction is particularly relevant when evaluating the growth hormone pathway.
What Remains Unknown
Research has not established whether Tesamorelin prevents lean-mass reduction during Retatrutide-associated weight loss.
Studies directly investigating this question would need to measure:
Skeletal muscle mass
Total and regional fat mass
Muscle strength and function
Visceral fat changes
Glucose regulation
Adverse effects and long-term outcomes
Without such evidence, claims about enhanced muscle preservation remain speculative.
Growth Hormone, IGF-1, and Glucose Regulation
One of the most important considerations in Tesamorelin research involves the relationship between growth hormone signaling and glucose metabolism.
Growth hormone can influence insulin sensitivity, glucose production, and nutrient utilization.
Although growth hormone participates in normal metabolic regulation, increased signaling may also contribute to impaired glucose tolerance in certain circumstances.
Tesamorelin's FDA-approved prescribing information includes warnings about glucose intolerance and diabetes.
It also addresses elevated IGF-1 levels and fluid retention.
These effects matter when comparing Tesamorelin with Retatrutide because metabolic pathways do not necessarily reinforce each other in beneficial ways.
Retatrutide's GLP-1 and GIP activity influences glucose-dependent insulin signaling.
Tesamorelin acts through a different endocrine pathway with its own effects on glucose metabolism.
The interaction between those systems cannot be predicted reliably from mechanism alone.
View FDA Tesamorelin Prescribing Information
Why Visceral Fat Research Extends Beyond Appearance
Visceral fat is commonly discussed in relation to abdominal appearance, but its scientific significance extends beyond cosmetic changes.
Researchers investigate visceral adipose tissue because it is associated with several processes involved in metabolic health.
These include lipid signaling, inflammatory activity, and insulin regulation.
Fat distribution can sometimes provide information that total body weight alone does not capture.
For example, two individuals with similar BMIs may have different concentrations of visceral adipose tissue.
Their metabolic profiles may also differ.
This is one reason studies examining regional fat compartments can provide valuable information beyond changes on a scale.
Nevertheless, reducing visceral fat does not automatically establish lower long-term cardiovascular risk.
Clinical outcomes must be evaluated directly rather than assumed from changes in imaging measurements.
Tesamorelin Versus Retatrutide: Comparing the Evidence
Research characteristicTesamorelinRetatrutidePrimary pathwayGHRH / growth hormone / IGF-1GLP-1 / GIP / glucagonMain metabolic interestVisceral fat and GH signalingBody weight and energy regulationMajor clinical endpointVisceral adipose tissue reductionTotal body-weight reductionHuman trial evidenceRandomized studies in HIV-associated fat abnormalitiesLarge obesity clinical trialsLiver fat findingsClinical data in adults with HIV and fatty liver diseaseBroader metabolic research under investigationGlucose considerationsGH-related effects on glucose toleranceIncretin and glucagon receptor signalingRegulatory statusApproved prescription formulations for a specific indicationInvestigational, not FDA-approvedEvidence for combined useNot clinically establishedNot clinically established
The most important difference is not simply the percentage of fat or weight reduction reported in each study.
It is what the trials measured, which populations they studied, and which biological mechanisms were involved.
Comparing results without considering these differences can create misleading conclusions.
Is Tesamorelin FDA-Approved?
Tesamorelin has an FDA-approved prescription formulation marketed as EGRIFTA WR.
Its approved indication is the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
The prescribing information specifically states that it is not indicated for general weight-loss management and describes the treatment as weight neutral.
The safety and effectiveness of that prescription formulation should not be assumed to apply to independently sourced research products.
Retatrutide remains investigational and has not received FDA approval as of October 2026.
Their different regulatory statuses are important when interpreting scientific findings.
The Future of Visceral Fat and Body Composition Research
Modern metabolic science increasingly examines body composition as a complex interaction between several biological systems.
Research areas include:
Hormonal appetite regulation
Visceral adipose tissue metabolism
Growth hormone and IGF-1 signaling
Liver fat accumulation
Skeletal muscle preservation
Insulin sensitivity
Fat distribution
Energy expenditure
Cardiometabolic risk
Retatrutide and Tesamorelin represent different approaches to studying these processes.
Retatrutide demonstrates the potential impact of simultaneously activating three hormone receptors involved in metabolic regulation.
Tesamorelin demonstrates how stimulation of the growth hormone pathway can influence visceral fat in certain clinical populations.
Future studies may clarify how changes in total weight, regional fat distribution, and endocrine signaling relate to long-term health outcomes.
Research directly evaluating combinations would be required before drawing conclusions about additional benefits or risks.
Frequently Asked Questions About Retatrutide and Tesamorelin
Is Tesamorelin the Same as Retatrutide?
No. Tesamorelin is a growth hormone-releasing hormone analog, while Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors.
Their mechanisms and primary clinical research outcomes differ.
Does Tesamorelin Reduce Visceral Fat?
Clinical trials have demonstrated reductions in visceral adipose tissue in adults with HIV-associated lipodystrophy.
Those findings do not establish equivalent benefits in all populations.
Does Retatrutide Specifically Target Visceral Fat?
Retatrutide has demonstrated substantial overall weight reduction and changes in metabolic measurements.
However, changes in total body weight or waist circumference should not automatically be interpreted as direct measurements of visceral fat.
Can Retatrutide and Tesamorelin Be Combined?
There is insufficient controlled human evidence to establish the safety or clinical benefit of combining these compounds.
Their different mechanisms provide questions for research, not a validated combination protocol.
Does Tesamorelin Preserve Muscle During Weight Loss?
Growth hormone participates in tissue and protein metabolism, but clinical studies have not established that Tesamorelin prevents muscle loss during Retatrutide-associated weight reduction.
Why Is IGF-1 Important in Tesamorelin Research?
IGF-1 is an important downstream component of growth hormone signaling and participates in numerous growth-related and metabolic processes.
Tesamorelin can increase IGF-1, which is relevant both to its biological effects and its safety considerations.
Final Thoughts: Two Different Approaches to Understanding Body Composition
The scientific interest surrounding Retatrutide and Tesamorelin comes from their distinct relationships with metabolic regulation and fat distribution.
Retatrutide has demonstrated significant reductions in overall body weight through triple hormone receptor activation.
Tesamorelin has demonstrated reductions in visceral abdominal fat in specific clinical populations through growth hormone-related signaling.
These findings illustrate an important principle:
Total body weight, visceral fat, and skeletal muscle composition are interconnected measurements, but they are not interchangeable.
Understanding these differences provides a more complete framework for evaluating metabolic research.
Future investigations may clarify how hormonal signaling, growth hormone regulation, and regional fat metabolism contribute to overall metabolic health.
For now, the available evidence supports understanding each compound's individual research findings without assuming additional benefits from combining them.
Published Scientific Research and References
1. Falutz J, et al. (2007). Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine.
2. Falutz J, et al. (2008). Long-Term Safety and Effects of Tesamorelin, a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Abdominal Fat Accumulation. AIDS.
3. Stanley TL, et al. (2019). Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV: A Randomised, Double-Blind, Multicentre Trial. The Lancet HIV.
4. Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
5. Eli Lilly and Company (2026). Retatrutide TRIUMPH-1 Phase 3 Clinical Trial Results.
6. U.S. Food and Drug Administration (2025). EGRIFTA WR (Tesamorelin) Prescribing Information.
View FDA Prescribing Information
Research Disclaimer: This article is provided by DeSoto Peptides for educational and scientific purposes. Retatrutide remains investigational and is not FDA-approved. Tesamorelin has an FDA-approved prescription formulation for a specific medical indication; this does not establish the safety or equivalence of independently sourced research materials. The discussion of these compounds does not constitute medical advice or a recommendation for combined administration.